Skip to main content

Table 3 Analysis of discrepancies between phenotypic data and the predictions obtained with different interpretation algorithms.a

From: DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes

  Interpretation algorithm
Inhibitor DR_SEQAN Retrogram ANRS HIVDB RegaInst
Zidovudine (AZT) 2.8 (36) 0 (31) 0 (35) 0 (33) 2.8 (36)
Zalcitabine (ddC) 11.1 (99) 0 (20) n.d.b n.d. 1.4 (27)
Didanosine (ddI) 17.8 (118) 0 (21) 11.7 (94) 0 (30) 3.3 (30)
Lamivudine (3TC) 3.9 (51) 2.1 (48) 7.1 (56) 4.2 (48) 4.2 (48)
Stavudine (d4T) 12.1 (58) 2.9 (34) 0 (35) 0 (32) 0 (57)
Abacavir (ABC) 19.8 (81) 0 (24) 19 (84) 3.3 (30) 3.8 (26)
Nevirapine (NVP) 13.4 (67) 14.0 (50) 8.8 (68) 4.8 (63) 4.0 (50)
Delavirdine (DLV) 5.4 (93) 3.3 (61) n.d. 3.4 (88) 3.2 (62)
Efavirenz (EFV) 11.5 (87) 12.8 (47) 10.8 (65) 1.6 (63) 6.3 (48)
Saquinavir (SQV) 8.9 (201) 8.1 (222) 30.0 (357) 6.4 (218) 14.4 (263)
Ritonavir (RTV) 4.6 (175) 5.4 (188) 6.5 (213) 4.1 (219) 7.6 (198)
Indinavir (IDV) 5.8 (190) 5.4 (185) 6.2 (211) 4.9 (205) 7.9 (228)
Nelfinavir (NFV) 5.6 (160) 6.0 (168) 13.9 (209) 2.9 (170) 13.0 (200)
Amprenavir (APV) 8.9 (223) 11.6 (216) 42.0 (483) 3.8 (208) 19.4 (304)
Lopinavir (LPV) 16.3 [0]c (43) 54.8 [28.6] (84) 61.6 [22.3] (112) 3.2 [3.2] (31) 37.5 [17.9] (56)
  1. a The reported values are percentages of isolates that are predicted to be sensitive to the inhibitor (S category in Table 1), but show a fold-increase of the IC50 for the inhibitor, which is above the cut-off values given in Table 2. Numbers in parenthesis indicate the total number of isolates predicted to be susceptible to the drug in the analyzed data set.
  2. b n.d., not determined.
  3. c The numbers shown between brackets represent the percentages obtained using a 10-fold cut-off value.